Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Isis Earns GSK Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Isis Earns GSK Milestone

Advances ISIS-TTR in FAP

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $2 million milestone payment from GlaxoSmithKline for the advancement of an ongoing Phase II/III study of ISIS-TTR in patients with familial amyloid polyneuropathy (FAP), a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.
 
The Phase II/III study is a randomized, double-blind, placebo-controlled, study will support an application for marketing approval of ISIS-TTR in patients with FAP. The study will measure the effects of ISIS-TTR on neurological dysfunction and on quality-of-life. 
 
To date, Isis has earned more than $20 million in upfront and milestone payments for advancing ISIS-TTR. Also, if GSK elects to exercise its option to exclusively license the ISIS-TTR program, Isis is eligible to receive a license fee, regulatory and sales milestones, and royalties on sales.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics